Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Duration: February 1, 2008
to
present
General Issues: Medicare/Medicaid , Health Issues , Copyright/Patent/Trademark , Insurance , Budget/Appropriations , Law Enforcement/Crime/Criminal Justice , Taxation/Internal Revenue Code , Miscellaneous Tariff Bills , Government Issues , Telecommunications , Trade (Domestic & Foreign)
Spending: about $32,549,408 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, U.S. Senate,
Related Foreign Entities:
Astellas Pharma Inc. (through 100% ownership of Astellas US Holding, Inc.) (Tokyo, JPN); contribution to lobbying: $0; ownership 100%; Astellas Pharma, Inc. (Tokyo, JPN); contribution to lobbying: $0; ownership 99%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Sarah D'Orsie
Professional Staff for Rep. Tom Davis; Clerk for Rep. Todd Platts; Intern for Sen. Rick Santorum
Ryan Ambrose
House Committee on Energy & Commerce, Clerk
Valarie Molaison
Congressional Science Fellow for Sen. Jon Tester (MT); Health Legislative Assistant for Sen. Sherrod Brown (OH)
James Rollins
None.
Jonathan Oehman
Legislative Correspondent, Legislative Asst., and Sr. Legislative Asst. for Rep. John Sullivan (OK Dist. 1); Legislative Director and then Chief of Staff for Rep. Bill Flores (TX Dist. 17)
Akshai Datta
Sr. Legislative Assistant to Rep. Ami Bera; Sr. Legislative Assistant to Rep. Bruce Baley; Legislative Assistant and Legislative Correspondent to Rep. Leonard Boswell.
Sr. Legislative Assistant to Rep. Ami Bera (CA Dist. 7); Sr. Legislative Assistant to Rep. Bruce Braley (IA Dist. 1); Legislative Assistant and Legislative Correspondent to Rep. Leonard Boswell (IA Dist. 3).
Stephen Rubright
Military Legislative Assistant and Foreign Policy Advisor to Sen. Kay Bailey Hutchison (TX); Military Legislative Assistant to Rep. Jeff Miller (FL-01).
Military Legislative Asst. & Foreign Policy Advisor for Sen. Kay Bailey Hutchison (TX); Military Legislative Assistant for Rep. Jeff Miller (FL)
Jonathan Oehmen
Legislative Correspondent, Legislative Assistant, and Sr. Legislative Assistant for Rep. John Sullivan (OK Dist. 1); Legislative Director and then Chief of Staff for Rep. Bill Flores (TX Dist. 17).
Michael Ruggiero
n/a
Samantha Ventimiglia
n/a
Mary-Lacey Reuther
n/a
Melissa Banashak
n/a
Margaret Long
n/a
Brian Corrigan
n/a
Michale Ruggiero
n/a
Joseph Devaney
n/a
Valerie Molaison
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 22.
Original Filing: 301574515.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness (no specific bills); H.R. 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 2666, MVP Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues related to Patient Drug User Fee Reauthorization (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 6743, WARM Act of 2023; H.R. 1826/S. 2821, PSA Screening for HIM Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2023
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301531740.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2023
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301511919.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301488702.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2023
Astellas Pharma US, Inc. filed a lobbying registration on April 10, 2023 for in-house lobbying efforts, effective April 1, 2023.
Original Filing: 301450028.xml
Issue(s) they said they’d lobby about: Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517). .
1st Quarter, 2023
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301466271.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2022
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301441293.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2022
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301416654.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 19, 2022.
Original Filing: 301386047.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301370882.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301337296.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301311464.xml
Lobbying Issues
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301291414.xml
Lobbying Issues
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301268084.xml
Lobbying Issues
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Out Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub.L.116-283).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301245640.xml
Lobbying Issues
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub. L. 116-283).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2020
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301218478.xml
Lobbying Issues
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2020
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301192043.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301178828.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301128164.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301078351.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019."
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301056342.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301035441.xml
Lobbying Issues
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1 - For the People Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2018
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2019.
Original Filing: 301012176.xml
Lobbying Issues
Issues related to Medicare Part D policy (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300996148.xml
Lobbying Issues
Issues related to Medicare Part D policy (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300977638.xml
Lobbying Issues
Issues related to Medicare Part D policy (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
Astellas Pharma US, Inc. filed a lobbying registration on May 22, 2018 for in-house lobbying efforts, effective May 17, 2018.
Original Filing: 300960402.xml
Issue(s) they said they’d lobby about: Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.). .
1st Quarter, 2018
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300956916.xml
Lobbying Issues
Issues related to Medicare Part D policy (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2017
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2018.
Original Filing: 300935612.xml
Lobbying Issues
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300913915.xml
Lobbying Issues
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
Astellas Pharma US, Inc. amended a lobbying report for in-house lobbying in Q22017 on Dec. 14, 2017
Original Filing: 300920359.xml
Lobbying Issues
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300894707.xml
Lobbying Issues
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300874533.xml
Lobbying Issues
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 23, 2017.
Original Filing: 300856933.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300837868.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300820099.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2016
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300803339.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2015
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300783855.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300764478.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300744076.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300726907.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300706831.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Issues related to the Medicare hospital outpatient issues (H.R. 4857, S. 2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300688438.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the Medicare hospital outpatient issues (H.R.4857).
Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2014
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 21, 2014.
Original Filing: 300668871.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the Medicare hospital outpatient issues (H.R.4857).
Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300648509.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) H.R. 4187
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2014.
Original Filing: 300622561.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Cancer Drug Coverage Parity Act (H.R. 1801, no specific Senate bill).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300607280.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Cancer Drug Coverage Parity Act (H.R. 1801, no specific Senate bill).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 22, 2013.
Original Filing: 300582524.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300561184.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300540688.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2012
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300520807.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734))
Issues related to implementation of the Prescription Drug User Fee Act (now Public Law 112-144)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2012
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2012.
Original Filing: 300498010.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734))
Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2012
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300475575.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300448196.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2011
Astellas Pharma US, Inc. amended a lobbying report for in-house lobbying in Q32011 on Jan. 20, 2012
Original Filing: 300448161.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to cancer research and treatment (no specific bills)
Issues related to drug safety (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2011
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300429302.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to cancer research and treatment (no specific bills)
Issues related to drug safety (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300404776.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to cancer research and treatment (no specific bills)
Issues related to drug safety (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300378181.xml
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the development of new antibiotics (no specific bills)
Issues related to the supply of medical isotopes (the American Medical Isotopes Production Act (S.99))
Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills)
Issues related to cancer research and treatment (no specific bills)
Issues related to drug safety (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to the pharmaceutical sales fee (no specific bills)
Issues related to the renewal of the R&D tax credit (no specific bills)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300347307.xml
Lobbying Issues
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565).
The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)).
Issues pertaining to community and healthcare associated infections.
Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)).
Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)).
Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)).
Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Issues related to development incentives for infectious disease products (HR 6331)).
Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2010.
Original Filing: 300318692.xml
Lobbying Issues
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565).
The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)).
Issues pertaining to community and healthcare associated infections.
Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)).
Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)).
Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)).
Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Issues related to development incentives for infectious disease products (HR 6331)).
Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
Astellas Pharma US, Inc. amended a lobbying report for in-house lobbying in Q22010 on Oct. 19, 2010
Original Filing: 300318666.xml
Lobbying Issues
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy
Coverage Act of 2009 (HR 574/S 254))
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565)Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging.
The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590),
and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)).
Issues pertaining to community and healthcare associated infections.
Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)).Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)).
Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 19, 2010.
Original Filing: 300293422.xml
Lobbying Issues
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy
Coverage Act of 2009 (HR 574/S 254))
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565)Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging.
The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590),
and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)).
Issues pertaining to community and healthcare associated infections.
Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)).Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)).
Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
Astellas Pharma US, Inc. amended a lobbying report for in-house lobbying in Q12010 on Oct. 19, 2010
Original Filing: 300318636.xml
Lobbying Issues
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy
CoverageAct of 2009 (HR 574/S 254))
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565)Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging.
The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590),
and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400))
Issues pertaining to community and healthcare associated infections
Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276))
Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872).
Issues related to comparative clinical effectiveness of immunosuppressant drugs.
Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Issues related to comparative clinical effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues related to Data Accountability bill (HR 2221)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 19, 2010.
Original Filing: 300264286.xml
Lobbying Issues
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy
CoverageAct of 2009 (HR 574/S 254))
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565)Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging.
The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590),
and the Affordable Health Care for America Act (HR 3962).
Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400))
Issues pertaining to community and healthcare associated infections
Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276))
Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872).
Issues related to comparative clinical effectiveness of immunosuppressant drugs.
Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Issues related to comparative clinical effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues related to Data Accountability bill (HR 2221)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300243937.xml
Lobbying Issues
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S 254); The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565); Issues related to Medicare Hospital Outpatient Prospective Payment System (HR 4371); Issues related to Medicare Part D dual eligibles rebate (see applicable bills on next page)(continued from previous page) - (America's Affordable Health Choices Act of 2009 (HR 3200); Service Member's Home Owenership Tax Act of 2009 (HR 3590); America's Healthy Future Act of 2009 (S 1796); Affordable Health Choices Act (S 1679); Affordable Health Care for America Act (HR 3962))
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (HR 2400); Issues pertaining to community and healthcare associated infections; Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)); Issues related to 340B program, drug importation and follow-on biologics (America's Affordable Health Choices Act of 2009 (HR 3200); Service Member's Home Ownership Tax Act of 2009 (HR 3590); America's Healthy Future Act of 2009 (S 1796); (continued next page)(continued from previous page) - Affordable Health Choices Act (S. 1679); Affordable Health Care for America Act (HR 3962)).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
The Data Accountability and Trust Act (HR 2221)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 16, 2009.
Original Filing: 300206581.xml
Lobbying Issues
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S254): The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565); Issues related to Medicare Hospital Outpatient Prospective Payment System; America's Affordable Health Choices Act (HR 3200): America's Healthy Future Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (HR 2400); issues pertaining to community and healthcare associated infections; issues pertaining to medical isotopes (HR 3276); issues related to 340B program; The Affordable Health Choices Act (S. 1679)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300183147.xml
Lobbying Issues
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to ensuring access to critical medications under Medicare Part D; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S 254); The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance (HR 2400); Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2009
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 15, 2009.
Original Filing: 300148339.xml
Lobbying Issues
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to ensuring access to critical medications under Medicare Part D; The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Jan. 16, 2009.
Original Filing: 300125037.xml
Lobbying Issues
S. 3560, QI Program Supplemental Funding Act of 2008, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S. Res. 454 and H. Res. 988, designating March 2008 as MRSA Awareness Month; Issues related to antibiotics and infectious dissease control.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on Oct. 9, 2008.
Original Filing: 300089751.xml
Lobbying Issues
H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
H.R. 6432, Animal Drug User Fee Amendments Act of 2008; S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S. 3560, QI Program Supplemental Funding Act of 2008; S. Res. 454 and H. Res. 988, designating March 2008 as MRSA Awareness Month; Issues related to antibiotics and infectious dissease control.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on July 18, 2008.
Original Filing: 300074696.xml
Lobbying Issues
S. 3101 and H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008 and S. 3118, the Preserving Access to Medicare Act of 2008; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions; and issues related to Medicaid prior authorization
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month; Issues related to Hatch-Waxman
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, Astellas Pharma US, Inc. had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300053660.xml
Lobbying Issues
Infectious disease issues, including S. 2313 and H.R. 3697 (the STAAR Act), S. 2278 (Community and Healthcare Associated Infections Reduction Act); prescription drug importation legislation; follow-on biologics legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, Section 2(b), Prior Authorization Programs; S. 1887, the Medicare Access to Critical Medications Act of 2007; H.R. 3061, the Medicare Part D Drug Class Protection Act of 2007; Implementation of Section 5001 (c) of the 2005 Deficit Reduction Act; HR 3282 & S 2320, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Medicare payment for imaging.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
Astellas Pharma US, Inc. filed a lobbying registration on Feb. 25, 2008 for in-house lobbying efforts, effective Feb. 1, 2008.
Original Filing: 300029352.xml
Issue(s) they said they’d lobby about: S. 2313 and H.R. 3697, the STAAR Act; S. 2278, Community and Healthcare Associated Infections Reduction Act; Issues relating to the implementation of Section 5001 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, Section 2(b), Prior Authorization Programs; S. 1887, the Medicare Access to Critical Medications Act of 2007; H.R. 3061, the
Medicare Part D Drug Class Protection Act of 2007 .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate